Photodynamic therapy combined with Winona barrier extreme cream for treatment of actinic keratosis: Efficacy and impact on RUNX3, Bcl-2, and ceramide levels

doi:10.3877/cma.j.issn.1674-0785.2022.10.009

Abstract

Abstract:

Objective

To evaluate the efficacy of photodynamic therapy (PDT) combined with Winona barrier extreme cream in the treatment of actinic keratosis (SK) and its effects on the levels of human runt related transcription factor 3 (RUNX3), B lymphoma-2 (Bcl-2), and ceramide (CER).

Methods

One hundred and sixteen patients with AK treated at West China Hospital of Sichuan University from January 2016 to June 2021 were randomly divided into a control group and a study group, with 58 cases in each group. The control group was treated with PDT, and the study group was treated with photodynamic therapy combined with Winona barrier extreme cream. The clinical efficacy, RUNX3, Bcl-2, CER, inflammatory factors, adverse reactions, recurrence rate, and quality of life were compared between the two groups.

Results

The complete remission rate in the study group (79.31%) was higher than that of the control group (62.07%; P＜0.05). There was no significant difference in the total effective rate, rate of adverse reactions, or recurrence rate between the two groups (P＞0.05). After treatment, TNF-α, IL-6, and ICAM-1 levels in the study group were lower than those in the control group, and Cer was higher than that in the control group (P＜0.05). There was no significant difference in the positive rates of RUNX3 and Bcl-2 between the two groups after treatment (P＞0.05). The DLQI score of the study group was lower than that of the control group (P＜0.05).

Conclusion

PDT combined with Winona barrier extreme cream is effective in the treatment of AK. The combination therapy has anti-inflammatory effects, promotes ceramide synthesis, improves the quality of life, and is associated with a low rate of adverse reactions and recurrence.

Key words: Actinic keratosis, Winona barrier cream, Photodynamic therapy, RUNX3, Bcl-2, Ceramide

Qin Yi, Xiaoqin Xie, Jiayan Liu, Erlong Li, Wenbin Zhao, Lifeng Yang, Rong Mei. Photodynamic therapy combined with Winona barrier extreme cream for treatment of actinic keratosis: Efficacy and impact on RUNX3, Bcl-2, and ceramide levels[J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(10): 970-974.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2022.10.009

https://zhlcyszz.cma-cmc.com.cn/EN/Y2022/V16/I10/970

Figures/Tables 5

References 22

1	何丽, 武小青, 李江斌, 等. 日光性角化病研究进展 [J]. 中国麻风皮肤病杂志, 2021, 37(1): 60-64.
2	景文文, 周永安. 复方甘草酸苷注射液冷喷与左西替利嗪片联合薇诺娜舒敏保湿特护霜治疗面部皮炎 [J]. 中国美容医学, 2021, 30(2): 33-36.
3	张海龙, 林永丽. 光动力疗法对尖锐湿疣性病患者的治疗效果及对LTN, HBD-2水平的影响 [J]. 广东医学, 2021, 42(3): 352-355.
4	马元龙, 张洲, 晓玲, 等. 4种方法治疗日光角化病的临床疗效比较 [J]. 内蒙古医科大学学报, 2020, 42(1): 66-68.
5	Moy LS, Frost D, Moy S. Photodynamic Therapy for photodamage, actinic keratosis, and acne in the cosmetic practice [J]. Facial Plast Surg Clin North Am, 2020, 28(1): 135-148.
6	李辉. 舒敏仪联合他克莫司及薇诺娜舒敏保湿特护霜治疗面部糖皮质激素依赖性皮炎疗效分析 [J]. 中国美容医学, 2020, 29(7): 29-31.
7	杨瑜萍, 陈俐均, 王洁君, 等. 舒敏治疗仪导入医学护肤品治疗敏感性皮肤的疗效观察 [J]. 中国美容医学, 2021, 30(7): 75-78.
8	de Berker D, McGregor JM, Mohd Mustapa MF, et al. British association of dermatologists' guidelines for the care of patients with actinic keratosis 2017 [J]. Br J Dermatol, 2017, 176(1): 20-43.
9	尹淑红, 王红妍. 含马齿苋提取物护肤品在治疗寻常性痤疮中的辅助作用研究 [J]. 中国美容医学, 2019, 28(8): 59-62.
10	王万伟, 薛世彦. ALA-PDT联合CO2激光治疗女性尖锐湿疣的疗效及对生活质量的影响 [J]. 中国医师杂志, 2019, 21(12): 4.
11	Nguyen M, Sandhu SS, Sivamani RK. Clinical utility of daylight photodynamic therapy in the treatment of actinic keratosis-a review of the literature [J]. Clin Cosmet Investig Dermatol, 2019, 12: 427-435.
12	马委委, 鲁严, 周炳荣. 光动力疗法在皮肤老化治疗中的基础和临床研究进展 [J]. 实用老年医学, 2020, 34(1): 12-15.
13	Carbone A, Sperduti I, De Simone P, et al. Daylight photodynamic therapy: experience in the treatment of actinic keratosis in the San Gallicano Institute (Rome) and a review of literature [J]. G Ital Dermatol Venereol, 2020, 155(3): 312-319.
14	尤艺璇, 涂颖, 许爱娥, 等. 薇诺娜舒敏保湿特护霜对新冠疫情防控期间医护人员佩戴医用口罩后皮肤屏障的修复 [J]. 中国皮肤性病学杂志, 2021, 35(2): 237-240.
15	Sousa ACDS, Campos MAC, Baptista AM, et al. Daylight photodynamic therapy in 25 patients with actinic keratosis and evaluation of efficacy by confocal microscopy [J]. Photodiagnosis Photodyn Ther, 2019, 25: 414-416.
16	Michelini M. Photodynamic therapy activated by intense pulsed light in the treatment of actinic keratosis [J]. G Ital Dermatol Venereol, 2020, 155(4): 470-476.
17	王贺聪, 何聪芬. 皮肤中神经酰胺的研究及应用现状 [J]. 日用化学工业, 2019, 48(1): 51-57.
18	吴姣娜, 郎文超, 付超, 等. 光动力疗法在光线性角化病治疗中的应用进展 [J]. 实用皮肤病学杂, 2021, 14(3): 156-159.
19	阚蓓, 韩莉, 张勇, 等. 日光性角化病中RUNX3和Bcl-2蛋白表达及其临床意义探讨 [J]. 中国美容医学, 2020, 29(1): 58-61.
20	周孔香. 二氧化碳激光联合艾拉光动力治疗尖锐湿疣的临床效果 [J]. 中国当代医药, 2019, 26(33): 114-116.
21	冯倩, 宋印娥. 不同浓度5-氨基酮戊酸光动力疗法对中重度痤疮患者的疗效比较 [J]. 实用临床医药杂志, 2020, 24(23): 16-19.
22	Dianzani C, Conforti C, Giuffrida R, et al. Current therapies for actinic keratosis [J]. Int J Dermatol, 2020, 59(6): 677-684.

组别	完全缓解	部分缓解	无效	总有效率
对照组（n=58）	36（62.07）	19（32.76）	3（5.17）	55（94.83）
研究组（n=58）	46（79.31）	11（18.97）	1（1.72）	57（98.28）
χ²值	4.161			1.036
P值	0.041			0.309

组别	完全缓解	部分缓解	无效	总有效率
对照组（n=58）	36（62.07）	19（32.76）	3（5.17）	55（94.83）
研究组（n=58）	46（79.31）	11（18.97）	1（1.72）	57（98.28）
χ²值	4.161			1.036
P值	0.041			0.309

组别	RUNX3（%）		Bcl-2（%）		Cer（μmol/g）
组别	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组（n=58）	35.28±4.15	7.62±2.65^a	30.63±4.24	6.30±1.79^a	0.26±0.10	0.41±0.29^a
研究组（n=58）	36.02±4.29	7.27±1.80^a	31.06±4.38	6.15±1.66^a	0.30±0.12	0.54±0.35^a
t值	0.944	0.262	0.537	0.468	1.950	2.178
P值	0.347	0.794	0.592	0.641	0.054	0.031

组别	RUNX3（%）		Bcl-2（%）		Cer（μmol/g）
组别	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组（n=58）	35.28±4.15	7.62±2.65^a	30.63±4.24	6.30±1.79^a	0.26±0.10	0.41±0.29^a
研究组（n=58）	36.02±4.29	7.27±1.80^a	31.06±4.38	6.15±1.66^a	0.30±0.12	0.54±0.35^a
t值	0.944	0.262	0.537	0.468	1.950	2.178
P值	0.347	0.794	0.592	0.641	0.054	0.031

组别	TNF-α（μg/ml）			IL-6（pg/ml）			ICAM-1（ng/L）
组别	治疗前	治疗后		治疗前	治疗后		治疗前	治疗后
对照组（n=58）	18.59±3.29	10.29±1.76^a		196.54±45.46	110.05±36.63^a		6.56±1.05	3.71±0.84^a
研究组（n=58）	18.80±3.42	8.30±1.54^a		194.93±43.11	82.47±30.53^a		6.69±1.11	2.64±0.56^a
t值	0.337		6.480	0.196		4.405	0.648	8.072
P值	0.737		＜0.001	0.845		＜0.001	0.518	＜0.001

Please choose a citation manager

Content to export